Insuline detemir (Levemir) dans l'etude predictive: resultats obtenus chez les patients diabetiques de type 1 de la cohorte belge.

Philips, Jean-Christophe; Scheen, André

Article (Scientific journals)

Philips, Jean-Christophe; Scheen, André

2009 • In Revue Médicale de Liège, 64 (3), p. 124-30

Peer reviewed

Permalink
https://hdl.handle.net/2268/23620

PubMed
19418931

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

200903_03.pdf

Publisher postprint (378.32 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Diabetes Mellitus, Type 1/drug therapy; Female; Humans; Hypoglycemia/chemically induced; Insulin/adverse effects/agonists/analogs & derivatives/therapeutic use; Male; Middle Aged

Abstract :

[en] Insulin detemir (Levemir) is a soluble human insulin analogue acylated with a 14-carbon fatty acid, which reversibly binds to albumin, thereby providing a more prolonged metabolic effect with lower variability as compared to NPH insulin taken as reference. Thanks to this pharmacokinetic and pharmacodynamic profile, insulin detemir is essentially used within a basal-bolus regimen. We report the results obtained in 232 type 1 diabetic patients recruited in Belgium in the frame of the international observational, open, prospective PREDICTIVE study. In patients initially treated with either NPH insulin or glargine, followed for 26 weeks, the shift to insulin detemir did not change HbA1c levels, but significantly reduced both the mean and the variability of fasting blood glucose levels while diminishing the risk of hypoglycaemic episodes, especially at night. Therefore, insulin detemir was associated with significantly improved quality of life. These changes were obtained with a slight increase in daily insulin doses but without weight gain.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Philips, Jean-Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Insuline detemir (Levemir) dans l'etude predictive: resultats obtenus chez les patients diabetiques de type 1 de la cohorte belge.

Alternative titles :

[en] Insulin detemir in the predictive study: results in patients with type 1 diabetes in the Belgian cohort

Publication date :

2009

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

124-30

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 24 September 2009

Statistics

Number of views

196 (1 by ULiège)

Number of downloads

337 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Bloomgarden Z.- Treatment issues in type 1 diabetes. Diabetes Care, 2002, 25, 230-238.
Diabetes Control and Complications Trial Research Group.- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.- Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med, 2000, 342, 381-389.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.- Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353, 2643-2653.
Radermecker RP.- Le risque hypoglycémique : implications therapeutiques. Rev Med Liége, 2005, 60, 329-334.
Bott S, Bott U, Berger M, et al.- Intensified insulin therapy and the risk of severe hypoglycaemia. Diabeto-logia, 1997, 40, 926-932.
Hirsch I.- Insulin analogues. N Engl J Med, 2005, 352, 174-183.
Philips JC, Radermecker RP.- L'insulinothérapie dans le diabète de type 1. Rev Med Liege, 2005, 60, 322-328.
Radermecker RP, Scheen AJ.- L'insuline biasparte 50 (Novomix®50). Rev Med Liège, 2008, 63, 688-692.
Scheen AJ, Radermecker RP, Philips JC, Paquot N.- Le médicament du mois : l'insuline détémir (Levemir®). Rev Med Liège, 2005, 60, 814-819.
Philips JC, Scheen AJ.- Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag, 2006, 2, 277-283.
Morales J.- Defining the role of insulin detemir in basal insulin therapy. Drugs, 2007, 67, 2557-2584.
Devries JH, Nattrass M, Pieber TR.- Refining basal insulin therapy : what have we learned in the age of analogues ? Diabetes Metab Res Rev, 2007, 23, 441-454.
Bush MA.- Intensive diabetes therapy and body weight : focus on insulin detemir. Endocrinol Metab Clin North Am, 2007, 36, 33-44.
Lüddeke H, Sreenan S, Aczel S, et al.- PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab, 2007, 9, 428-434.
Preumont V, Buysschaert M.- Safety and efficacy of insulin detemir in routine clinical practice : a 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE cohort. Acta Clin Belg, 2009, 64, 49-55.
Home P, Bartley P, Russell-Jones D, et al.- Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care, 2004, 27, 1081-1087.
Kjølendorf K, Ross GP, Pavlic-Renar I, et al.- Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabetic Med, 2006, 23, 729-735.
Wang F, Carabino JM, Vergara CM.- Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther, 2003, 25, 1541-1577.
Pieber T, Treichel H, Hompesch B, et al.- Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabetic Med, 2007, 25, 635-642.
Rosenstock J, Davies M, Home PD, et al.- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as addon to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 2008, 51, 408-416.
Dornhorst A, Luddeke H, Honka M, et al.- Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients : 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin, 2008, 24, 369-376.
Dornhorst A, Luddeke H, Sreenan S, et al.- Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract, 2008, 62, 659-665.
Fajardo Montanana C, Hernandez Herrero C, Rivas Fernandez M.- Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients : the PREDICTIVE BMI trial. Diabet Med, 2008, 25, 916-923.
Bartley PC, Bogoev M, Larsen J, Philotheou A.- Long- term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals : a 2-year, randomized, controlled trial. Diabetic Med, 2008, 25, 442-449.
Wutte A, Plank J, Bodenlenz M, et al.- Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes, 2007, 115, 461-467.
Heise T, Nosek L, Biilmann Rønn B, et al.- Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 2004, 53, 1614-1620.